PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|October 2, 2013
Cambridge Major Laboratories and AAIPharma To Merge
Author(s)Pharmaceutical Technology Editors
Cambridge Major Laboratories and AAIPharma Services plan to merge to form a global supplier of integrated CMC services.
Advertisement
, a CMO providing pharmaceutical API development and manufacturing, and AAIPharma Services, a provider of pharmaceutical analytical testing, product development, and manufacturing services, have announced their intent to merge to form a global supplier of integrated chemistry, manufacturing, and control (CMC) services. Financial terms of the merger were not disclosed. The merger is expected to close by the end of October 2013, subject to Hart-Scott-Rodino approval and other closing conditions.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement